Organon (OGN) Outperforms Broader Market: What You Need to Know
Organon (OGN) concluded the recent trading session at $20.47, signifying a +0.89% move from its prior day's close.
Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock
Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store.
Is Trending Stock Organon & Co. (OGN) a Buy Now?
Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Is Most-Watched Stock Organon & Co. (OGN) Worth Betting on Now?
Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Organon (OGN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Organon (OGN) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Organon (OGN) Surpasses Q2 Earnings Estimates
Organon (OGN) came out with quarterly earnings of $1.12 per share, beating the Zacks Consensus Estimate of $1.06 per share. This compares to earnings of $1.31 per share a year ago.
Top 4 stocks that could thrive if Kamala Harris wins the 2024 US election
As the 2024 US presidential election approaches, speculation about Kamala Harris potentially stepping into the Oval Office remains strong. Despite Donald Trump's assertion that Harris would be an easier opponent than Joe Biden, recent developments suggest Harris's presidency is a viable scenario.
Product Demand Likely to Aid Organon's (OGN) Q2 Earnings
Continued solid uptake of Organon's (OGN) products is expected to have driven second-quarter revenues.
Seeking Clues to Organon (OGN) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for Organon (OGN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2024.
Organon (OGN) Stock Falls Amid Market Uptick: What Investors Need to Know
In the latest trading session, Organon (OGN) closed at $21.86, marking a -1.84% move from the previous day.
Earnings Preview: Organon (OGN) Q2 Earnings Expected to Decline
Organon (OGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Organon: Upcoming Q2 Earnings Can Sustain Upward Momentum
Organon stock experienced significant downside pressure in 2023, however positive Q423 and Q124 earnings have led to a bull run. Organon's business includes women's health, biosimilars, and established brands divisions. The company was spun out of Merck & Co in 2020, and saddled with >$8bn debt. I anticipate Organon's upcoming Q2 2024 earnings will underline growth potential, with a focus on global sales, new product performance, and solid debt management.
